利奈唑啉
医学
不利影响
养生
药物基因组学
重症监护医学
药品
抗生素
基岩
肺结核
药理学
内科学
结核分枝杆菌
病理
万古霉素
金黄色葡萄球菌
细菌
遗传学
生物
微生物学
作者
Kamal Kishor,Neha Dhasmana,Shashank S. Kamble,Roshan Kumar Sahu
出处
期刊:Current Drug Metabolism
[Bentham Science]
日期:2015-10-28
卷期号:16 (7): 553-559
被引量:46
标识
DOI:10.2174/1389200216666151001121004
摘要
Treatment regimen recommended for resistant tuberculosis consists of various drugs and these drugs are prescribed for at least 12-15 months. Such a long duration therapy and high dose of antibiotics result in adverse drug reactions (ADRs). ADRs may lead to various complications in disease management like replacement of drugs, dose increment, therapy withdrawal, etc. Linezolid is one of those drugs, practiced as an anti-mycobacterial agent and it is an important member of drug regimen for MDR and XDR tuberculosis. Linezolid is a broad spectrum antibiotic known for its unique mechanism of inhibition of resistant pathogenic strains. However, it causes serious adverse effects like thrombocytopenia, optic neuropathy, peripheral neuropathy, lactic acidosis, etc. Literature suggests that Linezolid can cause severe ADRs which affect patient compliance and hinder in therapy to a larger extent. Recent studies confirm the possibility of ADRs to be predicted with genetic make-up of individuals. To effectively deliver the available treatment regimen and ensure patient compliance, it is important to manage ADRs more efficiently. The role of pharmacogenomics in reducing adverse drug effects has been recently explored. In the present review, we discussed about Linezolid induced adverse drug reactions, mechanisms and genetic associations. Keywords: Adverse drug reactions, anti-tuberculosis drugs, drug interactions, linezolid, optic neuropathy, thrombocytopenia.
科研通智能强力驱动
Strongly Powered by AbleSci AI